SCHEMBL380982

SCHEMBL380982

CCOC(=O)C(O)C1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
PPM1B O75688 1/20 0.43
PTPN1 P18031 1/20 0.43
PPP1CC P36873 1/20 0.43
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.39
HSD17B10 Q99714 1/20 0.39
NPSR1 Q6W5P4 2/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
TSHR P16473 2/20 0.37
GAA P10253 2/20 0.37
ALOX15 P16050 1/20 0.37
MGAM O43451 1/20 0.37
SI P14410 1/20 0.37
MGAM2 Q2M2H8 1/20 0.37
SOAT1 P35610 1/20 0.37
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29998004 1.00 L3MBTL1 (0.46) L3MBTL1PPM1BPTPN1PPP1CCALDH1A1
SCHEMBL5407976 0.91 ALDH1A1 (0.46) L3MBTL1PPM1BPTPN1PPP1CCALDH1A1
SCHEMBL2256208 0.90 ALDH1A1 (0.53) L3MBTL1PPM1BPTPN1ALDH1A1NPSR1
SCHEMBL16837858 0.83 ALDH1A1 (0.40) L3MBTL1PPM1BPTPN1PPP1CCALDH1A1
SCHEMBL9209640 0.79 L3MBTL1 (0.61) L3MBTL1ALDH1A1LMNAHSD17B10NPSR1
SCHEMBL28833924 0.78 L3MBTL1 (0.43) L3MBTL1ALDH1A1LMNAHSD17B10NPSR1
SCHEMBL28833926 0.78 L3MBTL1 (0.43) L3MBTL1ALDH1A1LMNAHSD17B10NPSR1
SCHEMBL4680121 0.77 L3MBTL1 (0.46) L3MBTL1ALDH1A1LMNAHSD17B10NPSR1
SCHEMBL1485389 0.76
SCHEMBL24759326 0.76 L3MBTL1 (0.33) L3MBTL1PPM1BPTPN1PPP1CC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12545662-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2026-02-10 US disclosed
US-20250136577-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2025-05-01 US disclosed
EP-4472734-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2024-12-11 EP disclosed
US-11987574-B2 MK2 inhibitors and uses thereof XINTHERA, INC. (US) 2024-05-21 US disclosed
EP-4313970-A1 MK2 INHIBITORS AND USES THEREOF Xinthera, Inc. (US) 2024-02-07 EP disclosed
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-23 US disclosed
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-11-23 US disclosed
WO-2023180189-A1 MPRO TARGETING ANTIVIRAL COMPOUNDS EXSCIENTIA AI LIMITED (GB) 2023-09-28 WO disclosed
US-20230265076-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-08-24 US disclosed
US-20230265076-A1 MK2 INHIBITORS AND USES THEREOF XINTHERA, INC. 2023-08-24 US disclosed
US-20170190734-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES Selcia Ltd. (GB) 2017-07-06 US disclosed
US-9642889-B2 Macrocyclic inhibitors of Flaviviridae viruses GILEAD SCIENCES, INC. (US) 2017-05-09 US disclosed
US-20160220633-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES CYPRALIS LIMITED (GB) 2016-08-04 US disclosed
US-20150361132-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES CYPRALIS LIMITED (GB) 2015-12-17 US disclosed
US-9062092-B2 Macrocyclic inhibitors of Flaviviridae viruses GILEAD SCIENCES, INC. (US) 2015-06-23 US disclosed
US-20150099781-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-09 US disclosed
US-8969342-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections BRANDEIS UNIVERSITY (US) 2015-03-03 US disclosed
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections University of Georgia Foundation, Inc. (US) 2012-04-26 US disclosed
EP-2408753-A2 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS Brandeis University (US) 2012-01-25 EP disclosed
WO-2010108187-A2 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS BRANDEIS UNIVERSITY (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11987574-B2 MK2 inhibitors and uses thereof MKNK2, ENPP2, MAPKAPK2 L3MBTL1 4666/4885PPM1B 66/4885PTPN1 888/4885
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 L3MBTL1 2101/4885PPM1B 1754/4885PTPN1 1670/4885
US-20160220633-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES HAVCR2, ZC3HAV1, HCCS L3MBTL1 2766/4885PPM1B 2601/4885PTPN1 2697/4885
US-20250136577-A1 HETEROCYCLIC DERIVATIVES AS MALT1 INHIBITORS MALT1, SQSTM1, FKBP1A L3MBTL1 3415/4885PPM1B 56/4885PTPN1 144/4885
US-20230373969-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, ENPP2, MAPKAPK2 L3MBTL1 4666/4885PPM1B 66/4885PTPN1 888/4885
US-20170190734-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES HAVCR2, ZC3HAV1, HCCS L3MBTL1 2766/4885PPM1B 2601/4885PTPN1 2697/4885
US-20230265076-A1 MK2 INHIBITORS AND USES THEREOF MKNK2, ENPP2, MAPKAPK2 L3MBTL1 4666/4885PPM1B 66/4885PTPN1 888/4885
US-20150361132-A1 MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES HAVCR2, ZC3HAV1, HCCS L3MBTL1 2766/4885PPM1B 2601/4885PTPN1 2697/4885
US-20150099781-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 L3MBTL1 2101/4885PPM1B 1754/4885PTPN1 1670/4885
US-12545662-B2 MK2 inhibitors and uses thereof NR3C2, NR2C2, AGTR2 L3MBTL1 4290/4885PPM1B 669/4885PTPN1 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.